


SOME ORGANOPHOSPHATE INSECTICIDES AND HERBICIDES

VOLUME 112



This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 3–10 March 2015

LYON, FRANCE - 2017

IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
MALATHION	36
1. Exposure Data.....	36
1.1 Identification of the agent	36
1.2 Production and use.....	37
1.3 Measurement and analysis.....	39
1.4 Occurrence and exposure.....	39

2. Studies of Cancer in Humans.....	46
2.1 Scope of available epidemiological studies.....	46
2.2 Summary of frequently cited epidemiological studies.....	51
2.3 Cohort studies on malathion.....	61
2.4 Case-control studies on lympho-haematopoietic cancers and malathion.....	72
2.5 Case-control studies on other cancers.....	81
2.6 Meta-analysis.....	86
3. Cancer in Experimental Animals.....	86
3.1 Mouse.....	86
3.2 Rat.....	91
4. Mechanistic and Other Relevant Data.....	100
4.1 Absorption, distribution, metabolism, and excretion.....	100
4.2 Mechanisms of carcinogenesis.....	106
4.3 Data relevant to comparisons across agents and end-points.....	127
4.4 Susceptibility.....	133
4.5 Other adverse effects.....	135
5. Summary of Data Reported.....	137
5.1 Exposure data.....	137
5.2 Human carcinogenicity data.....	138
5.3 Animal carcinogenicity data.....	140
5.4 Mechanistic and other relevant data.....	140
6. Evaluation.....	142
6.1 Cancer in humans.....	142
6.2 Cancer in experimental animals.....	142
6.3 Overall evaluation.....	142
6.4 Rationale.....	142
References.....	143
PARATHION.....	160
1. Exposure Data.....	160
1.1 Identification of the agent.....	160
1.2 Production and use.....	161
1.3 Measurement and analysis.....	162
1.4 Occurrence and exposure.....	162
2. Cancer in Humans.....	164
2.1 Introduction.....	164
2.2 Cohort studies.....	164
2.3 Case-control studies.....	171
2.4 Meta-analyses.....	173
3. Cancer in Experimental Animals.....	173
3.1 Mouse.....	173
3.2 Rat.....	175
4. Mechanistic and Other Relevant Data.....	182
4.1 Toxicokinetic data.....	182
4.2 Mechanisms of carcinogenesis.....	188
4.3 Data relevant to comparisons across agents and end-points.....	200

4.4 Susceptibility	207
4.5 Other adverse effects	208
5. Summary of Data Reported	209
5.1 Exposure data.....	209
5.2 Human carcinogenicity data.....	209
5.3 Animal carcinogenicity data.....	210
5.4 Mechanistic and other relevant data.....	211
6. Evaluation.....	212
6.1 Cancer in humans.....	212
6.2 Cancer in experimental animals.....	212
6.3 Overall evaluation	212
References.....	212
DIAZINON.....	223
1. Exposure Data.....	223
1.1 Identification of the agent	223
1.2 Production and use.....	224
1.3 Measurement and analysis.....	225
1.4 Occurrence and exposure.....	225
2. Cancer in Humans	229
2.1 Summary of frequently cited epidemiological studies.....	229
2.2 Cohort studies	229
2.3 Case-control studies on lympho-haematopoietic cancers	249
2.4 Case-control studies on other cancers.....	259
2.5 Meta-analysis.....	267
3. Cancer in Experimental Animals	267
3.1 Mouse.....	267
3.2 Rat	268
4. Mechanistic and Other Relevant Data	269
4.1 Toxicokinetic data	269
4.2 Mechanisms of carcinogenesis.....	276
4.3 Data relevant to comparisons across agents and end-points	293
4.4 Susceptibility	300
4.5 Other adverse effects	300
5. Summary of Data Reported	301
5.1 Exposure data.....	301
5.2 Human carcinogenicity data.....	302
5.3 Animal carcinogenicity data.....	304
5.4 Mechanistic and other relevant data.....	305
6. Evaluation.....	306
6.1 Cancer in humans.....	306
6.2 Cancer in experimental animals.....	306
6.3 Overall evaluation	306
6.4 Rationale	306
References.....	306

GLYPHOSATE	321
1. Exposure Data.....	321
1.1 Identification of the agent.....	321
1.2 Production and use.....	322
1.3 Measurement and analysis.....	324
1.4 Occurrence and exposure.....	325
2. Cancer in Humans.....	331
2.0 General discussion of epidemiological studies.....	331
2.1 Cohort studies.....	331
2.2 Case-control studies on non-Hodgkin lymphoma, multiple myeloma, and leukaemia.....	336
2.3 Case-control studies on other cancer sites.....	349
2.4 Meta-analyses.....	350
3. Cancer in Experimental Animals.....	350
3.1 Mouse.....	350
3.2 Rat.....	355
4. Mechanistic and Other Relevant Data.....	361
4.1 Toxicokinetic data.....	361
4.2 Mechanisms of carcinogenesis.....	365
4.3 Data relevant to comparisons across agents and end-points.....	393
4.4 Cancer susceptibility data.....	393
4.5 Other adverse effects.....	393
5. Summary of Data Reported.....	394
5.1 Exposure data.....	394
5.2 Human carcinogenicity data.....	395
5.3 Animal carcinogenicity data.....	396
5.4 Other relevant data.....	396
6. Evaluation.....	398
6.1 Cancer in humans.....	398
6.2 Cancer in experimental animals.....	398
6.3 Overall evaluation.....	398
6.4 Rationale.....	398
References.....	399
 TETRACHLORVINPHOS	 413
1. Exposure Data.....	413
1.1 Identification of the agent.....	413
1.2 Production and use.....	414
1.3 Measurement and analysis.....	415
1.4 Occurrence and exposure.....	416
2. Cancer in Humans.....	417
2.1 Summary of frequently cited epidemiological studies.....	417
2.2 Cohort studies.....	417
2.3 Case-control studies on lympho-haematopoietic cancers.....	418
3. Cancer in Experimental Animals.....	421
3.1 Mouse.....	421
3.2 Rat.....	427

4. Mechanistic and Other Relevant Data	430
4.1 Toxicokinetic data	430
4.2 Mechanisms of carcinogenesis.....	433
4.3 Data relevant to comparisons across agents and end-points	438
4.4 Susceptibility	442
4.5 Other adverse effects	442
5. Summary of data reported.....	443
5.1 Exposure data.....	443
5.2 Human carcinogenicity data.....	443
5.3 Animal carcinogenicity data.....	444
5.4 Mechanistic and other relevant data.....	444
6. Evaluation.....	445
6.1 Cancer in humans.....	445
6.2 Cancer in experimental animals.....	445
6.3 Overall evaluation	445
References.....	445
LIST OF ABBREVIATIONS.....	450
ANNEX 1. SUPPLEMENTAL MATERIAL.....	452

